Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Peking Union Medical College Hospital is the lead sponsor of 282 current clinical trials in our China register. 187 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Lenvatinib, Pembrolizumab and Camrelizumab. The most-studied condition is Breast Cancer.

ClinicalTrials.gov trials by status

Recruiting18766%
Not yet open5218%
Active, closed2910%
By invitation145%

Trials by phase

Observational8430%
Not applicable6824%
Phase 26021%
Phase EARLY_PHASE1197%
Phase 4197%
Phase 1/2166%
Phase 372%
Phase 152%
Phase 2/341%

Clinical trials sponsored by Peking Union Medical College Hospital

282 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors NCT06632860 · Iodine-resistant Thyroid Cancer, Meningioma, NETs Drug: 18-FDG	Phase EARLY_PHASE1	Recruiting	2024-08	China
Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT NCT07062523 · ClinicalTrials.gov ↗ · Sjogren's Syndrome Drug: 68Ga-FAPI	Phase 1/2	Recruiting	2024-07	China
Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) NCT05559645 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Drug: Sunvozertinib	Not applicable	Recruiting	2021-11	China
Diagnostic Value of Deep Learning-Based Rapid MRI in Preoperative Evaluation of Acute Cholecystitis NCT07551375 · ClinicalTrials.gov ↗ · Acute Cholecystitis	Observational	Recruiting	2024-06	China
Efficacy and Safety of Subcutaneous Injection of XH-02 in the Treatment of Adult Hypoparathyroidism NCT07530705 · ClinicalTrials.gov ↗ · Hypoparathyroidism	Phase 1/2	Recruiting	2025-11	China
68Ga-NYM096 PET/CT in Various Kinds of Cancer NCT07144748 · ClinicalTrials.gov ↗ · Cancer	Not applicable	Recruiting	2025-08	China
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer NCT06035016 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, Early-stage Breast Cancer Drugs: Capecitabine, Pyrotinib	Observational	Recruiting	2023-06	China
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer NCT07704177 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms Immunotherapy Drugs: Adebrelimab, Lenvatinib, Trastuzumab Rezetecan	Phase 2	Recruiting	2026-04	China
First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma NCT06070740 · ClinicalTrials.gov ↗ · Gastrointestinal Neuroendocrine Carcinoma	Phase 2	Recruiting	2023-11	China
Observational Cohort Study of Chronic Viral Infection in the Central Nervous System NCT07512518 · ClinicalTrials.gov ↗ · Progressive Multifocal Leukoencephalopathy, Immune Checkpoint Inhibitors	Observational	Recruiting	2023-02	China
The Study of Differences in Eosinophil Function and Subsets in Patients With Eosinophilic Pulmonary Diseases NCT06944418 · ClinicalTrials.gov ↗ · Eosinophil Subtype, Eosinophilic Pulmonary Diseases	Observational	Recruiting	2024-01	China
Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer NCT05871762 · ClinicalTrials.gov ↗ · Rectal Neoplasms	Observational	Recruiting	2023-06	China
Safety and Efficacy Study of PUMCH-E111 Injection in Subjects With RLBP1 Related Inherited Retinal Dystrophy NCT07656753 · ClinicalTrials.gov ↗ · Inherited Retinal Dystrophy, Inherited Retinal Disease	Phase EARLY_PHASE1	Recruiting	2026-02	China
Online Adaptive Radiotherapy for Cervical Cancer NCT06562166 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 2	Recruiting	2024-09	China
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer NCT07670273 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms Immunotherapy Drugs: Adebrelimab, Lenvatinib, Trastuzumab Rezetecan	Phase 2	Recruiting	2026-04	China
Establishing Prospective Mediastinal Tumor Database of PUMCH NCT06421805 · ClinicalTrials.gov ↗ · Thymic Epithelial Tumor, Teratoma, Thymic Cyst	Observational	Recruiting	2012-01	China
The Comparision of Minimally-invasive and Open Pancreaticoduodenectomy for Pancreatic Cancer NCT03747588 · ClinicalTrials.gov ↗ · Pancreatic Carcinoma, Surgery	Not applicable	Recruiting	2018-12	China
National Registry of IRPF in China NCT04314323 · ClinicalTrials.gov ↗ · Idiopathic Retroperitoneal Fibrosis	Observational	Recruiting	2020-03	China
Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer NCT05751018 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drug: Pyrotinib	Phase 2	Recruiting	2021-12	China
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors NCT06056362 · ClinicalTrials.gov ↗ · Neuroendocrine Tumors	Phase 1/2	Recruiting	2023-03	China
Spatial Multi-omics and Intelligent Early Warning of Pancreatic Cancer Cachexia NCT07670286 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Cachexia; Cancer; Sarcopenia	Observational	Recruiting	2026-04	China
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer NCT05802407 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Resectable Carcinoma	Not applicable	Recruiting	2023-02	China
The Research of Integrated Traditional Chinese and Western Medicine on Hypothalamic Amenorrhea NCT07580950 · ClinicalTrials.gov ↗ · Functional Hypothalamic Amenorrhea	Phase 4	Recruiting	2025-10	China
Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma NCT07288931 · ClinicalTrials.gov ↗ · Pheochromocytoma/Paraganglioma (PPGL) Drugs: Diagnostic Test: 68Ga-DOTATATE, Diagnostic Test: Al18F-NOTA-LM3	Not applicable	Recruiting	2024-08	China
Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer NCT05424692 · ClinicalTrials.gov ↗ · Colon Cancer, Rectal Cancer, Chemotherapy Effect Drug: Ivonescimab	Not applicable	Recruiting	2021-09	China
Reasons for Non-reversal of Temporary Stomas After Surgeries of Mid-low Rectal Cancer （NORESTO Study） NCT06194708 · ClinicalTrials.gov ↗ · Rectal Cancer	Observational	Recruiting	2023-05	China
Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma NCT07014150 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Resectable Drugs: Iparomlimab and Tuvonralimab, Lenvatinib	Phase 2	Recruiting	2025-06	China
Minimal Vitrectomy Surgery for Epiretinal Membrane NCT07019896 · ClinicalTrials.gov ↗ · Epiretinal Membrane, Macular Edema (ME), Nuclear Cataract	Not applicable	Recruiting	2024-12	China
Photoacoustic/Ultrasound Imaging of Brown Adipose Tissue Activity NCT07327684 · ClinicalTrials.gov ↗ · Insulin Resistance, Metabolic Syndrome	Not applicable	Recruiting	2025-05	China
Development and Validation of Microbiota and Metabolite-based Prediction Model for Recurrence of High-risk Colorectal Polyps After Polypectomy NCT06957626 · ClinicalTrials.gov ↗ · Colorectal Polyp, Colorectal Cancer Recurrent, Colorectal Adenoma	Observational	Recruiting	2023-04	China
A National Registry on Chinese Patients With Lymphangioleiomyomatosis NCT03193892 · ClinicalTrials.gov ↗ · Pulmonary Function	Observational	Recruiting	2017-01	China
Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome NCT07350707 · ClinicalTrials.gov ↗ · Cushing s Syndrome	Phase 1/2	Recruiting	2023-06	China
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor NCT05069220 · ClinicalTrials.gov ↗ · Neuroendocrine Tumor, Neuroblastoma, Pheochromocytoma Drugs: 18F-MFBG, 68Ga-Dotatate	Phase EARLY_PHASE1	Recruiting	2021-09	China
Establishment and Application of Digital Diagnosis and Treatment System for Sarcopenia NCT06380777 · ClinicalTrials.gov ↗ · Sarcopenia	Observational	Recruiting	2023-09	China
Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6 NCT06028672 · ClinicalTrials.gov ↗ · Gestational Trophoblastic Neoplasia Drugs: Actinomycin-D, Toripalimab	Not applicable	Recruiting	2023-09	China
Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture NCT05866029 · ClinicalTrials.gov ↗ · Osteoporotic Fractures Drug: Denosumab	Not applicable	Recruiting	2023-05	China
Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge NCT07453342 · ClinicalTrials.gov ↗ · Immune-Related Adverse Events	Observational	Recruiting	2023-01	China
RCT of Tocilizumab for Anti-MDA5+DM NCT07377058 · ClinicalTrials.gov ↗ · Dermatomyositis Drug: Tocilizumab	Not applicable	Recruiting	2025-11	China
68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC. NCT06613269 · ClinicalTrials.gov ↗ · Clear Cell Renal Cell Carcinoma	Phase 2	Recruiting	2024-03	China
An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC NCT07452003 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drug: Iparomlimab and Tuvonralimab	Not applicable	Recruiting	2026-01	China
Weight Cycling on Hyperandrogenemia and Insulin Resistance in Polycystic Ovary Syndrome NCT06545721 · ClinicalTrials.gov ↗ · Polycystic Ovary Syndrome	Not applicable	Recruiting	2024-08	China
Large Segmentation Radiotherapy ± Deep Inspiration Breath Hold(DIBH) for Left Breast Cancer NCT06660628 · ClinicalTrials.gov ↗ · Breast Cancer	Not applicable	Recruiting	2024-08	China
Perioperative Statins to Prevent AFib After Lung Surgery NCT07727681 · ClinicalTrials.gov ↗ · Postoperative Atrial Fibrillation, Lung Surgery Drug: Atorvastatin	Phase 4	Recruiting	2026-08	China
AI in Predicting Polyp Pathology and Endoscopic Classification NCT06773832 · ClinicalTrials.gov ↗ · Colorectal Polyps	Observational	Recruiting	2025-01	China
Multimodal PET Imaging in the Diagnosis and Treatment of Pelvic Tumors NCT06774209 · ClinicalTrials.gov ↗ · Endometrial Cancer	Not applicable	Recruiting	2024-03	China
Bowel Sound in Predicting the Severity of Acute Pancreatitis: Protocol of a Prospective, Multi-center Study NCT06867120 · ClinicalTrials.gov ↗ · Acute Pancreatitis (AP), Severe Acute Pancreatitis	Observational	Recruiting	2024-04	China
Machine Learning Model Based on Baroreflex Sensitivity for Predicting Post-Induction Hypotension in Elderly Patients NCT07618416 · ClinicalTrials.gov ↗ · Post Induction Hypotension	Observational	Recruiting	2026-06	China
Prone Position Assessed by 3D EIT NCT07083973 · ClinicalTrials.gov ↗ · ARDS (Acute Respiratory Distress Syndrome), Respiratory Failure	Observational	Recruiting	2024-10	China
Observation of Exhaled VOC Biomarkers Characteristics in Admitted Women with Breast Ultrasound BI-RADS 4 Grade NCT06489158 · ClinicalTrials.gov ↗ · Breast Cancer	Observational	Recruiting	2024-09	China
A Randomized Controlled Trial of 3D Airway Reconstruction for Precise Double-Lumen Bronchial Intubation NCT07719959 · ClinicalTrials.gov ↗ · Pulmonary Nodules	Not applicable	Recruiting	2026-08	China
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis NCT07079423 · ClinicalTrials.gov ↗ · AL Amyloidosis Drug: Teclistamab	Phase 2	Recruiting	2025-06	China
Teclistamab in Previously Treated AL Amyloidosis NCT06935162 · ClinicalTrials.gov ↗ · AL Amyloidosis Drug: Teclistamab	Phase 2	Recruiting	2025-05	China
Lung Recruitment Assessed by 2D/3D-EIT and R/I Ratio in Acute Respiratory Failure Patients With Mechanical Ventilation NCT07379242 · ClinicalTrials.gov ↗ · Acute Respiratory Failure (ARF)	Observational	Recruiting	2025-09	China
Clinical Characteristics and Analysis of Pituitary Complex and Rare Diseases NCT06435195 · ClinicalTrials.gov ↗ · Pituitary Diseases	Observational	Recruiting	2024-01	China
Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases NCT05476627 · ClinicalTrials.gov ↗ · Chronic Kidney Diseases, Hypertension, Diabetes Mellitus	Observational	Recruiting	2022-07	China
99mTc-MY6349 SPECT/CT Imaging in Trop2-positive Triple-negative Breast Cancer NCT06104085 · ClinicalTrials.gov ↗ · Breast Cancer	Not applicable	Recruiting	2023-09	China
Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer NCT07267078 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 2	Recruiting	2025-05	China
Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients NCT06375473 · ClinicalTrials.gov ↗ · Pancreatic Cancer Drug: Irinotecan liposome II combination therapy	Observational	Recruiting	2024-04	China
A Prospective Cohort Study of IRPF in China NCT04312854 · ClinicalTrials.gov ↗ · Idiopathic Retroperitoneal Fibrosis	Observational	Recruiting	2020-01	China
Study on the Application of Liquid Chromatography-Tandem Mass Spectrometry for the Determination of Aldosterone and Renin Activity in the Diagnosis of Primary Aldosteronism by Captopril Test NCT07691801 · ClinicalTrials.gov ↗ · Primary Aldosteronism	Observational	Recruiting	2025-04	China
Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer NCT06230471 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms Immunotherapy	Phase 2	Recruiting	2023-01	China
Glofitamab in Chinese Patients With R/R DLBCL NCT06481826 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma Drug: Glofitamab	Observational	Recruiting	2024-01	China
Photoacoustic/Ultrasound Imaging for Breast Nodule Diagnosis, Molecular Classification, and Neoadjuvant Chemotherapy Response Evaluation NCT06908291 · ClinicalTrials.gov ↗ · Breast Masses, Breast Cancer, Breast Cancer Treated with Neoadjuvant Chemotherapy	Not applicable	Recruiting	2023-06	China
Wearable Accelerometers for Predicting Perioperative Risk in Elderly Patients NCT07621120 · ClinicalTrials.gov ↗ · Post Induction Hypotension	Observational	Recruiting	2026-06	China
Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer NCT06411678 · ClinicalTrials.gov ↗ · Breast Cancer	Phase EARLY_PHASE1	Recruiting	2024-05	China
Effects of Lactulose on Gut Microbiota and Metabolism in Diabetic Constipated Patients NCT07065942 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Constipation - Functional	Not applicable	Recruiting	2023-07	China
TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination NCT06478537 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia Drugs: Aspirin, Hetrombopag, Hetrombopag Olamine	Phase 2	Recruiting	2024-06	China
A Prospective Cohort Study of IgG4RD in China NCT01670695 · ClinicalTrials.gov ↗ · IgG4-related Disease	Observational	Recruiting	2012-01	China
Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer NCT06363006 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 1	Recruiting	2024-03	China
Correlation Study Between SMA Blood Flow Reactivity and Acute Gastrointestinal Injury in Critically Ill Patients NCT07001943 · ClinicalTrials.gov ↗ · Intestinal Ischemia, Critical Illness, Enteral Nutrition Feeding	Observational	Recruiting	2025-06	China
68Ga-NYM096 PET/ CT for the Detection of ccRCC in Presurgical Patients With Complex Cystic Renal Leision NCT06949215 · ClinicalTrials.gov ↗ · ccRCC, Complex Renal Cyst	Phase 2	Recruiting	2025-05	China
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block NCT06023784 · ClinicalTrials.gov ↗ · Left Bundle Branch Area Pacing, Right Ventricular Pacing, Atrioventricular Block	Not applicable	Recruiting	2023-09	China
Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients NCT06194617 · ClinicalTrials.gov ↗ · Pulmonary Embolism, Venous Thromboembolism, Anticoagulant-induced Bleeding	Observational	Recruiting	2021-04	China
Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease NCT05330923 · ClinicalTrials.gov ↗ · Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fibrosis	Observational	Recruiting	2022-01	China
Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia NCT05139095 · ClinicalTrials.gov ↗ · Gestational Trophoblastic Neoplasia Drugs: Apatinib, Camrelizumab	Phase 2	Recruiting	2022-01	China
68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients NCT05324332 · ClinicalTrials.gov ↗ · Prostate Cancer Drug: 68Ga-PSMA-11	Not applicable	Recruiting	2022-04	China
Risk Factor Assessment for Acute Pulmonary Hypertension Crisis NCT07653958 · ClinicalTrials.gov ↗ · Pulmonary Hypertension, Pulmonary Hypertension Crisis	Observational	Recruiting	2026-06	China
Gut and Vaginal Microbiota Profile Study for HIV Women NCT05996016 · ClinicalTrials.gov ↗ · HPV, HIV Infections, Vaginal Microbiota	Observational	Recruiting	2017-01	China
Sirolimus in the Treatment of Refractory/Relapsed wAIHA NCT05925023 · ClinicalTrials.gov ↗ · Warm Autoimmune Hemolytic Anemia Drug: Sirolimus	Not applicable	Recruiting	2023-06	China
Lenalidomide in the Treatment of Mucosal Behçet's Syndrome NCT05449548 · ClinicalTrials.gov ↗ · Oral Ulcer	Not applicable	Recruiting	2023-04	China
Anesthesia Neurodevelopmental Impact in Congenital Scoliosis Children NCT06315933 · ClinicalTrials.gov ↗ · General Anesthetics Toxicity	Observational	Recruiting	2020-07	China
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy. NCT07282262 · ClinicalTrials.gov ↗ · Biliary Tract Cancer Drugs: Ivosidenib, Lenvatinib	Phase 2	Recruiting	2024-05	China
Simplification of Oral Sodium Loading Test in the Diagnosis of Primary Aldosteronism: 2-day Replacing 3-day Method NCT06750172 · ClinicalTrials.gov ↗ · Primary Aldosteronism	Observational	Recruiting	2023-12	China
VR Interventions to Reduce the Prevalence of Delirium in ICU Patients NCT05525702 · ClinicalTrials.gov ↗ · Delirium	Not applicable	Recruiting	2023-12	China
Al18F-NOTA-LM3 PET/CT in Patients With TIO NCT07366099 · ClinicalTrials.gov ↗ · Tumor-Induced Osteomalacia Drugs: Diagnostic Test: 68Ga-DOTATATE, Diagnostic Test: Al18F-NOTA-LM3	Not applicable	Recruiting	2023-03	China
A Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism NCT07540286 · ClinicalTrials.gov ↗ · Hypoparathyroidism	Phase 2	Recruiting	2026-04	China
A National Registry on Chinese Patients With Cystic Fibrosis NCT05289245 · ClinicalTrials.gov ↗ · Pulmonary Function	Observational	Recruiting	2022-04	China
Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Malignant Tumor NCT06844110 · ClinicalTrials.gov ↗ · Tumor Immunity	Not applicable	Recruiting	2025-03	China
Clinical Research of Tapering UDCA in PBC Patients With a Complete Response NCT04650243 · ClinicalTrials.gov ↗ · Primary Biliary Cholangitis	Phase 4	Recruiting	2020-01	China
68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients NCT05549024 · ClinicalTrials.gov ↗ · Breast Cancer, Prostate Cancer, Brain Tumor Drug: 18F-FDG	Phase EARLY_PHASE1	Recruiting	2022-08	China
Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study NCT05860400 · ClinicalTrials.gov ↗ · Coronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis	Observational	Recruiting	2023-05	China
Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer NCT06898437 · ClinicalTrials.gov ↗ · Radioiodine Refractory Differentiated Thyroid Cancer	Phase EARLY_PHASE1	Recruiting	2025-03	China
Hypofractionated Online Adaptive Radiotherapy of Breast Cancer NCT06568705 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	2024-09	China
Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer NCT07108127 · ClinicalTrials.gov ↗ · Rectal Cancer, HER2-positive Drug: Xelox	Phase 2	Recruiting	2025-06	China
Lidocaine for LESS Postoperative Shoulder Pain Alleviation NCT07537127 · ClinicalTrials.gov ↗ · Cystectomy, Myomectomy	Not applicable	Recruiting	2025-12	China
Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention NCT03378934 · ClinicalTrials.gov ↗ · Coronary Artery Disease, Percutaneous Coronary Intervention Drugs: Aspirin, Berberine, Clopidogrel	Phase 4	Recruiting	2018-09	China
Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A NCT06802055 · ClinicalTrials.gov ↗ · Aplastic Anaemia Drugs: Cyclosporin A, Sirolimus	Phase 2	Recruiting	2025-01	China
Orelabrutinib in the Treatment of Relapsed/Refractory AIHA NCT07453368 · ClinicalTrials.gov ↗ · Autoimmune Hemolytic Anemia (AIHA)	Phase 2	Recruiting	2026-03	China
An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer. NCT07101237 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (ICC), Primary Liver Cancer	Observational	Recruiting	2024-08	China
Geno-radiomics Based Model for Evaluation of Immunotherapy and Targeted Therapy for Advanced Soft Tissue Sarcoma NCT06062927 · ClinicalTrials.gov ↗ · Advanced Soft Tissue Sarcoma	Observational	Recruiting	2023-02	China

Showing the 100 most recently updated of 282 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Peking Union Medical College Hospital trials

90 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 50 more in the trial list above.

Conditions in Peking Union Medical College Hospital trials

377 conditions

Breast Cancer9 Pancreatic Cancer7 Non Small Cell Lung Cancer4Biliary Tract Neoplasms Immunotherapy4Diminished Ovarian Reserve (DOR)4Primary Aldosteronism4 Coronary Artery Disease4 Cervical Cancer3 Surgery3 Biliary Tract Cancer3 Non-small Cell Lung Cancer3 Rectal Cancer3Gestational Trophoblastic Neoplasia3ARDS (Acute Respiratory Distress Syndrome)3 Respiratory Failure3 Hepatocellular Carcinoma3 Prostate Cancer3 Radiotherapy3Constipation - Functional3Critical Illness3Coronary Artery Stenosis3Coronary Artery Restenosis3Coronary Artery Disease Progression3Sjogren's Syndrome2

By trial register

Register	Trials	Recruiting
Clinical trials in China	282	187

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Breast Cancer

Sponsor	Trials
Fudan University	48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	21
Second Affiliated Hospital, Zhejiang University, School of Medicine	19
AstraZeneca	15
Shengjing Hospital	15
Pfizer	12
Sichuan Baili Pharmaceutical	12
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	12
Hoffmann-La Roche	10
Ruijin Hospital	10

Sponsors with the most current trials registered for this condition.

Questions about Peking Union Medical College Hospital trials

How many clinical trials does Peking Union Medical College Hospital sponsor?

Peking Union Medical College Hospital is the lead sponsor of 282 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Peking Union Medical College Hospital trials recruiting?

Yes. 187 of its 282 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Peking Union Medical College Hospital testing?

Its current trials name 90 drugs and biologicals as interventions. The most frequent are Lenvatinib (6), Pembrolizumab (5), Camrelizumab (4), Adebrelimab (3) and Apatinib (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Peking Union Medical College Hospital clinical trials